Advasa Holdings Inc. (ADBT) Stock Analysis

Verdict: AVOID

Post-IPO price collapse (-80.0%) and thin 12.6% gross margins outweigh revenue growth, creating extreme speculative risk.

Investment score: 20/100

Analysis as of 2026-09-04

Is Advasa Holdings Inc. stock worth reviewing? AI model thesis

The model views ADBT as a high-risk speculative asset following an 80.02% session collapse to $0.3437. While FY2026 revenue grew 72.9% to $17.37M, gross margins remain razor-thin at 12.6% and cash flow turned negative (-$1.40M FCF). Combined with minimal employee headcount (2 reported) and zero quarterly earnings track record, the model strongly favors avoidance.

7-factor investment score

Valuation: 15/100 (weight 20%)
Financial Health: 30/100 (weight 15%)
Technical Momentum: 10/100 (weight 15%)
Earnings Quality: 25/100 (weight 15%)
Insider Sentiment: 30/100 (weight 10%)
Analyst Consensus: 30/100 (weight 10%)
Risk-Adjusted Return: 10/100 (weight 15%)

Advasa Holdings Inc. opportunities and risks

What speaks for ADBT

Enterprise Earned Wage Access (EWA) adoption in Japan drove revenue up 72.9% YoY to $17.37M in FY2026.

What speaks against ADBT

Severe gross margin compression down to 12.6% in FY2026 ($2.18M GP on $17.37M revenue) from 22.8% in FY2025.

Frequently asked questions about Advasa Holdings Inc. (ADBT)

Is ADBT stock a good investment?

The cached TradeMates AI model rates Advasa Holdings Inc. as AVOID with an investment score of 20/100. The model views ADBT as a high-risk speculative asset following an 80.02% session collapse to $0.3437. While FY2026 revenue grew 72.9% to $17.37M, gross margins remain razor-thin at 12.6% and cash flow turned negative (-$1.40M FCF). Combined with minimal employee headcount (2 reported) and zero quarterly earnings track record, the model strongly favors avoidance. This is algorithmic model output, not personal investment advice.

Is ADBT stock a buy?

The TradeMates model verdict for ADBT is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.